BEFORE & AFTER PHOTOS
SPONSORED
Daxxify before and after photo courtesy of Dr. Karyn Grossman, board-certified dermatologic surgeon in Santa Monica, California. Results may vary.
Daxxify before and after photo courtesy of Dr. Karyn Grossman, board-certified dermatologic surgeon in Santa Monica, California. Results may vary.
Daxxify before and after photo courtesy of Dr. Karyn Grossman, board-certified dermatologic surgeon in Santa Monica, California. Results may vary.
Daxxify (daxibotulinumtoxinA-lanm) is an injectable wrinkle treatment thatâs FDA approved to improve the appearance of moderate to severe frown lines, the glabellar lines or âelevensâ between the eyebrows. In August 2023, the drug was also approved by the FDA for the treatment of cervical dystonia in adults.
This injectable neuromodulator may also be used off-label to treat other facial lines and wrinklesâlike forehead furrows, crowâs feet, and bunny lines (on the nose)âas well as platysmal bands in the neck and dimpling of the chin. It can also be injected into the masseter muscles to soften a square, bulky jaw while reducing the clenching and grinding associated with TMJ.Â
Like Botox, Dysport, and Xeomin, Daxxify (a.k.a. Daxi) works by temporarily blocking the release of the neurotransmitter that makes facial muscles move. This smooths âdynamic wrinklesâ and prevents new expression lines from forming.
Revance Therapeutics, the makers of Daxxify, say itâs uniquely long-lasting: clinical studies show an improvement in frown lines for six to nine months, compared to the standard three- to five-month result offered by previously approved neuromodulators, like Botox.Â
âThe studies showed that a two-point or greater improvement in glabellar linesâfrom severe to mild or moderate to none on the validated scaleâwas maintained for at least 24 weeks after a single treatment,â says Dr. Hema Sundaram, a board-certified dermatologist in Fairfax, Virginia. âAbout 50% of the patients maintained improvements in glabellar lines for at least 26 to 28 weeks.â
Daxxify owes its longevity to a novel peptide, which allows it to bind more effectively to the nerve cell membrane, where the receptors for botulinum toxins reside. According to Dr. Jason Bloom, a board-certified facial plastic surgeon in Philadelphia, pairing the peptide to the toxin molecule gives it a positive charge, drawing it to the negatively charged cell membrane.
The proprietary peptide in Daxxify also eliminates the need for animal-derived stabilizing proteins, like the human serum albumin found in all other neuromodulators.
âEach botulinum toxin differs in formulationâin particular, the components used to âholdâ the toxin peptides as a stable active complex for absorption,â explains Dr. Heidi Waldorf, a board-certified dermatologist in Nanuet, New York, who was an investigator on the Daxxify clinical trials. âDaxxify contains no human serum albumin [HSA], which is used by the other companies as a stabilizer, to keep the botulinum toxin complexes from sticking onto the vial surface. Although HSA poses no additional risk, some patients may prefer a product without human components.â (The human albumin used in Botox is derived from purified, donated blood.)
New York City-based, board-certified dermatologist Dr. Ron Shelton, says that he and other providers have noticed another unique benefit of Daxxify, one they havenât seen with other toxins: the skinâs texture often looks improved post-treatment. âIt is a more dewey, brighter, and smoother complexion,â he notes.Â









